SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CECONI, Claudio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 20.873
AS - Asia 10.007
EU - Europa 5.958
SA - Sud America 1.734
AF - Africa 213
OC - Oceania 36
Continente sconosciuto - Info sul continente non disponibili 5
Totale 38.826
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.567
SG - Singapore 3.893
CN - Cina 2.568
IT - Italia 1.860
BR - Brasile 1.361
UA - Ucraina 1.265
HK - Hong Kong 918
VN - Vietnam 873
DE - Germania 710
TR - Turchia 635
GB - Regno Unito 531
FI - Finlandia 431
FR - Francia 312
RU - Federazione Russa 299
JP - Giappone 194
SE - Svezia 194
IN - India 174
MX - Messico 155
BD - Bangladesh 134
AR - Argentina 129
ID - Indonesia 99
CA - Canada 97
IQ - Iraq 80
ZA - Sudafrica 75
PL - Polonia 72
EC - Ecuador 61
PK - Pakistan 59
CO - Colombia 55
ES - Italia 53
PH - Filippine 51
AT - Austria 47
MY - Malesia 46
NL - Olanda 43
UZ - Uzbekistan 40
VE - Venezuela 37
CL - Cile 33
MA - Marocco 32
SA - Arabia Saudita 30
AU - Australia 27
KE - Kenya 24
PY - Paraguay 24
KR - Corea 22
AE - Emirati Arabi Uniti 21
TN - Tunisia 21
EG - Egitto 19
GE - Georgia 18
PE - Perù 18
LT - Lituania 17
TH - Thailandia 17
JO - Giordania 16
JM - Giamaica 14
BE - Belgio 12
RO - Romania 12
IE - Irlanda 11
LB - Libano 11
NP - Nepal 11
CZ - Repubblica Ceca 10
TW - Taiwan 10
AL - Albania 9
PS - Palestinian Territory 9
PT - Portogallo 9
CH - Svizzera 8
CR - Costa Rica 8
DZ - Algeria 8
IL - Israele 8
IR - Iran 8
KZ - Kazakistan 8
OM - Oman 8
BG - Bulgaria 7
BO - Bolivia 7
KG - Kirghizistan 7
SN - Senegal 7
UY - Uruguay 7
AM - Armenia 6
GR - Grecia 6
MD - Moldavia 6
MN - Mongolia 6
NZ - Nuova Zelanda 6
RS - Serbia 6
BH - Bahrain 5
ET - Etiopia 5
EU - Europa 5
GT - Guatemala 5
HN - Honduras 5
KW - Kuwait 5
TT - Trinidad e Tobago 5
AO - Angola 4
AZ - Azerbaigian 4
BY - Bielorussia 4
HR - Croazia 4
MM - Myanmar 4
PA - Panama 4
BA - Bosnia-Erzegovina 3
DO - Repubblica Dominicana 3
HU - Ungheria 3
LV - Lettonia 3
LY - Libia 3
NI - Nicaragua 3
NO - Norvegia 3
EE - Estonia 2
Totale 38.784
Salva come PNG Salva come JPEG
Città #
Singapore 2.431
Woodbridge 2.376
Fairfield 2.368
Ashburn 1.919
Houston 1.365
Jacksonville 1.350
Seattle 991
Hong Kong 902
Chandler 887
Ann Arbor 886
San Jose 824
Wilmington 809
Cambridge 795
Santa Clara 689
Beijing 577
Dallas 510
Izmir 433
Nanjing 410
Princeton 349
Ho Chi Minh City 306
Boardman 232
San Diego 232
Lauterbourg 209
Hanoi 196
Tokyo 178
New York 160
Los Angeles 158
Milan 158
Helsinki 148
Shenyang 135
Nanchang 119
Rome 114
Moscow 112
São Paulo 103
Hefei 101
Mexico City 98
Hebei 81
San Mateo 77
Changsha 75
Falls Church 68
Ferrara 68
Jiaxing 67
Tianjin 67
Warsaw 64
London 62
Chicago 58
Jinan 58
Shanghai 58
Council Bluffs 54
Munich 52
Naples 51
Zhengzhou 48
Mountain View 47
Verona 44
Jakarta 40
Ningbo 40
Rio de Janeiro 40
Bremen 38
Da Nang 38
Redwood City 37
Taizhou 37
Tashkent 37
Frankfurt am Main 35
Johannesburg 34
The Dalles 34
Haiphong 32
Brooklyn 31
Philadelphia 31
Guangzhou 27
Montreal 27
Norwalk 27
Baghdad 26
Orem 26
Toronto 26
Addison 25
Chennai 25
Tappahannock 25
Napoli 24
Columbus 22
Indiana 22
Kuala Lumpur 22
Kunming 22
Atlanta 21
Belo Horizonte 21
Biên Hòa 21
Campinas 21
Curitiba 21
Guarulhos 21
Hangzhou 21
Porto Alegre 21
Stockholm 21
Brasília 20
Dhaka 20
Falkenstein 20
Istanbul 20
Nuremberg 20
Vienna 20
Buffalo 19
Des Moines 19
Goiânia 19
Totale 25.945
Salva come PNG Salva come JPEG
Nome #
IL METABOLISMO DEL MIOCARDIO ISCHEMICO IBERNATO E STORDITO: DIFFERENZA TRA NECROSI E APOPTOSI 1.832
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 339
2015 ESC Guidelines for the diagnosis and management of pericardial diseases The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS) 274
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC 263
Chronic Obstructive Pulmonary Disease and Ischemic Heart Disease Comorbidity: Overview of Mechanisms and Clinical Management 260
Echocardiography, Spirometry, and Systemic Acute-Phase Inflammatory Proteins in Smokers with COPD or CHF: An Observational Study 250
Abnormalities of Left Ventricular Function in Asymptomatic Patients with Systemic Sclerosis Using Doppler Measures of Myocardial Strain 241
A way forward to the elimination of conflict of interest for experts involved in regulatory medicine and guidelines 237
ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes 231
Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review 230
Uric acid and coronary artery disease: An elusive link deserving further attention 224
ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes (Am Journal of Cardiovasc Drugs (2011) 11:3 (189-98)) 217
Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL 216
Incremental exercise using progressive versus constant pedaling rates: A study in cardlac patients 214
Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis 211
A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals 210
2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. 208
Effects of temperature on myocardial calcium homeostasis and mitochondrial function during ischemia and reperfusion 206
Advanced glycation end products and its soluble receptor (sRAGE) are increased in chronic heart failure but not in chronic obstructive pulmonary disease. 195
Enhanced expression and activity of xanthine oxidoreductase in the failing heart. 194
Efficacy of angiotensin-converting enzyme inhibitors in secondary prevention 192
Prolonged propionyl-L-carnitine pre-treatment of rabbit: Biochemical, hemodynamic and electrophysiological effects on myocardium 190
The combined effect of subcutaneous granulocyte- colony stimulating factor and myocardial contrast echocardiography with intravenous infusion of sulfur hexafluoride on post-infarction left ventricular function, the RIGENERA 2.0 trial: Study protocol for a randomized controlled trial 189
Third Universal Definition of Myocardial Infarction 188
Guidelines on myocardial revascularization 187
ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: Results from the PERTINENT study 187
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). 187
The ACE-inhibitor Perindoprilat has high selectivity for bradykinin binding sites of human somatic ACE 185
Multiparametric flow cytometric characterization of circulating stem cell subsets in patients with myocardial infarction: correlation with clinical and biological data 184
Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) 184
[Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI] 182
Neglected COPD and chronic comorbidities in elderly patients with chronic heart failure 181
Tumor necrosis factor-α receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: The cytokine-activation and long-term prognosis in myocardial infarction (C-ALPHA) study 180
Link between chronic obstructive pulmonary disease and coronary artery disease: Implication for clinical practice 180
Activation of the neuroendocrine response in heart failure: adaptive or maladaptive process? 179
Neuroendocrine Control of the Cardiovascular System in Heart Failure 176
Bradykinin and coronary artery disease 176
Oxygen free radicals and myocardial damage: Protective role of thiol-containing agents 175
Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies 173
Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE 172
Traditional and new composite endpoints in heart failure clinical trials: Facilitating comprehensive efficacy assessments and improving trial efficiency 171
Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD 171
Reduction of oxidative stress by carvedilol: Role in maintenance of ischaemic myocardium viability 170
Is stunning an important component of preconditioning? 170
[The double face of oxygen. An introduction to cardiac pathology caused by oxidation injury] 170
[Heart failure: an endothelial disorder?] 170
[Comparative protective effect of gallopamil in myocardial ischemia and reperfusion] 170
Postinfarction Left Ventricular Free Wall Rupture: Original Management and Surgical Technique 169
Heart rate reduction by pharmacological If current inhibition 169
Third Universal Definition of Myocardial Infarction 169
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation 169
Myocardial damage during ischaemia and reperfusion 167
The prospective impact of chronic obstructive pulmonary disease on short-term prognosis of patients with chronic heart failure 167
ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). 167
Secondary Prevention of CAD with ACE Inhibitors: A Struggle Between Life and Death of the Endothelium 167
In vitro administration of ergothioneine failed to protect isolated ischaemic and reperfused rabbit heart 166
Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy 166
Time course of human atrial natriuretic factor release during cardiopulmonary bypass in mitral valve and coronary artery diseased patients 165
The effect of propionyl-L-carnitine on the ischemic and reperfused intact myocardium and on their derived mitochondria 164
Occurrence of oxidative stress during reperfusion of the human heart 164
Specific properties and effect of perindopril in controlling the renin-angiotensin system 164
Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology 164
Effect of superoxide generation on rat heart mitochondrial pyruvate utilization 163
Pathophysiological role of heart rate: from ischaemia to left ventricular dysfunction 163
Right heart failure chronically stimulates heat shock protein 72 in heart and liver but not in other tissues. 163
Effects of endotoxic shock on neuronal NOS and calcium transients in rat cardiac myocytes 163
Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease 163
Tumor necrosis factor in congestive heart failure: a mechanism of disease for the new millennium? 162
Long-term treatment with ivabradine in post-myocardial infarcted rats counteracts f-channel overexpression 162
Evidence against malondialdehyde bound to cellular constituents in phospholipid peroxidation 162
Ischemic Heart Disease. 130 Questions & Answers 161
Different outcomes of the reperfused myocardium: insights into the comments of stunning and hibernation. 161
New insights on myocardial pyridine nucleotides and thiol redox state in ischemia and reperfusion damage 160
Chromogranin A in heart failure - A novel neurohumoral factor and a predictor for mortality 160
Oxygen Free Radicals in Shock 160
Effects of iloprost (ZK 36374) on glutathione status during ischaemia and reperfusion of rabbit isolated hearts 159
Interleukin-6, but not pentraxin 3, predicts adverse clinical outcomes on short-term prognosis of patients with incipient heart failure 159
Efficacy of Ivabradine in Combination with Beta-Blocker Versus Uptitration of Beta-Blocker in Patients with Stable Angina 159
Mechanisms of remodelling - A question of life (stem cell production) and death (myocyte apoptosis) - 159
Oltre la dissincronia quali fattori determinano la risposta alla terapia di resincronizzazione cardiaca? 158
Angiotensin II overproduction: enemy of the vessel wall 158
Effect of D-600 on ischemic and reperfused rabbit myocardium: relation with timing and modality of administration. 158
Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease 158
Selective and specific I f inhibition with ivabradine: New perspectives for the treatment of cardiovascular disease 157
Differential action of ACE inhibitors on the eNOS pathway 156
Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling. 156
Studio dei progenitori emopoietici circolanti in pazienti con infarto del miocardio 156
Plasma levels of atrial natriuretic factor and urinary excretion of arginine vasopressin and catecholamines in children with congenital heart disease effect of cardiac surgery 155
Protective effect of propionyl-L-carnitine against ischaemia and reperfusion-damage 155
Mechanical vs. electrical dyssynchrony for CRTselection in patients with HF 155
Relevance of apoptosis in influencing recovery of hibernating myocardium 155
Specific and selective I-f inhibition: expected clinical benefits from pure heart rate reduction in coronary patients 155
Left ventricular dysfunction due to stunning and hibernation in patients 154
Different sites of action of diltiazem, nifedipine and verapamil on myocardial, coronary and aortic muscle 153
Third universal definition of myocardial infarction 153
The utility of echocardiography in elderly smokers with COPD and of spirometry in elderly smokers with CHF 153
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). 153
Skeletal muscle abnormalities in rats with experimentally induced heart hypertrophy and failure 151
Metabolic changes during post-ischaemic reperfusion. 151
Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction 151
Totale 19.578
Salva come PNG Salva come JPEG
Categoria #
all - tutte 161.644
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 6.922
Totale 168.566
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021504 0 0 0 0 0 0 0 0 0 0 353 151
2021/20222.999 85 374 306 82 107 137 167 151 100 187 262 1.041
2022/20232.315 277 29 78 259 391 382 52 243 315 24 152 113
2023/20241.176 178 166 77 50 66 130 48 31 18 64 56 292
2024/20254.108 83 106 341 104 527 279 138 304 693 545 480 508
2025/202611.739 1.001 540 1.422 1.663 1.420 839 1.212 825 1.318 1.452 47 0
Totale 39.072